@article {1513,
	title = {HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.},
	journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
	volume = {48},
	year = {2009},
	month = {2009 Mar 15},
	pages = {806-15},
	abstract = {The combination of tenofovir and emtricitabine shows promise as HIV preexposure prophylaxis (PrEP). We sought to forecast clinical, epidemiologic, and economic outcomes of PrEP, taking into account uncertainties regarding efficacy, the risks of developing drug resistance and toxicity, behavioral disinhibition, and drug costs.},
	keywords = {Adenine, Adult, Anti-HIV Agents, Chemoprevention, Computer Simulation, Cost-Benefit Analysis, Deoxycytidine, HIV Infections, Homosexuality, Humans, Male, Phosphonic Acids, Risk Assessment, United States},
	issn = {1537-6591},
	doi = {10.1086/597095},
	author = {Paltiel, A David and Freedberg, Kenneth A and Scott, Callie A and Schackman, Bruce R and Losina, Elena and Wang, Bingxia and Seage, George R and Sloan, Caroline E and Sax, Paul E and Walensky, Rochelle P}
}
